Clinical Perspectives

CD47 Antibody Magrolimab in Combination with Azacitidine Effective in MDS and AML Patients

December 10, 2019

Heme Tumor Board

At the 2019 American Society of Hematology conference, Dr. David Sallman shared how Magrolimab + AZA is a novel immunotherapy regimen that blocks a key macrophage checkpoint. 

Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. Dr. Sallman discussed findings from an ongoing phase Ib trial.

“As a clinician caring for patients with MDS, I am reminded daily of the limitations of existing standard-of-care medicines, which are appropriate for a small fraction of people and leave nearly 75% receiving only supportive care or watchful waiting,” said Dr. Sallman. “The data that continue to emerge from this clinical trial are encouraging, suggesting that the combination of magrolimab and azacitidine may offer the first new therapeutic regimen in over a decade, with the potential to induce meaningful and lasting responses in patients with higher-risk disease. Importantly, these results also support magrolimab’s tolerability profile, further differentiating it as a safe treatment that may be used even in more fragile, sicker, and older patients.”

Dr. David Sallman, Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center


Magrolimab+AZA is a novel immunotherapy regimen that blocks a key macrophage checkpoint. The combination therapy continues to be well tolerated with robust activity in MDS and AML patients with an ORR of 100% and 69%, respectively. High rates of putative LSC eradication suggest potential durable responses, with no median duration of response yet reached. Initial data indicate that 5F9+AZA may be particularly effective in TP53 mutant patients, a treatment-refractory subgroup.

Expansion cohorts are ongoing (NCT03248479) with registrational studies in MDS being initiated. Watch more about this trial from ASH here or here.